Kymab secures US$90 million funding

Kymab, a leading monoclonal antibody biopharmaceutical company, announced today that it has successfully raised an additional US$50 million to complete a US$90 million Series B financing. The US$50 million is being invested by Woodford Patient Capital Trust plc and Malin Corporation plc. This follows the first US$40 million Series B investment from the Wellcome Trust and the Bill & Melinda Gates Foundation.